Determinants of Bacille Calmette-Guérin scarification in Danish children
Background: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for de...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020326001 |
id |
doaj-71768f5b5a764a31a36bcd7dd948a6f4 |
---|---|
record_format |
Article |
spelling |
doaj-71768f5b5a764a31a36bcd7dd948a6f42021-02-05T16:13:10ZengElsevierHeliyon2405-84402021-01-0171e05757Determinants of Bacille Calmette-Guérin scarification in Danish childrenTrine Mølbæk Jensen0Signe Kjeldgaard Jensen1Nina Marie Birk2Andreas Rieckmann3Thomas Hoffmann4Christine Stabell Benn5Dorthe Lisbeth Jeppesen6Ole Pryds7Thomas Nørrelykke Nissen8Department of Pediatrics, Copenhagen University Hospital, Hvidovre, Denmark; Corresponding author.Department of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkResearch Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Denmark; Section of Epidemiology, Department of Public Health, University of Copenhagen, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkResearch Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Denmark; Odense Patient Data Explorative Network (OPEN), Odense University Hospital/Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; Bandim Health Project, Guinea-BissauDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkBackground: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for developing a BCG-scar and for BCG scar size following neonatal BCG vaccination. Methods: At three Danish hospitals, newborns were randomized 1:1 to BCG vaccination or no BCG vaccination. The infants were invited for a clinical examination at the ages of 3 and 13 months. At 13 months, the scar site was inspected and scar size measured. We investigated three groups of determinants; external, parental, and individual-level determinants on relative scar prevalence and differences in median scar sizes. Results: Among 2118 BCG vaccinated infants, 2039 (96 %) were examined at 13 months; 1857 of these (91 %) had developed a BCG-scar. Compared with Copenhagen University Hospital, Hvidovre (85 %), Copenhagen University Hospital, Rigshospitalet had a scar prevalence of 95 % (adjusted Prevalence ratio (aPR) = 1.24 [CI 95 %: 1.18 to 1.30]); it was 93 % at Kolding Hospital (aPR 1.27 [CI 95 %: 1.19 to 1.35]). Increasing vaccine experience was positively associated with developing a scar and with scar size. Conclusion: Across multiple potential determinants of BCG scaring and size, logistical factors dominated. The results support that injection technique is an important determinant of developing a scar. Given the strong link between having a BCG scar and subsequent health, improved BCG vaccination technique could play a major role for child health.http://www.sciencedirect.com/science/article/pii/S2405844020326001BCG vaccineBCG scarNon-specific effectsHeterologous immunity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Trine Mølbæk Jensen Signe Kjeldgaard Jensen Nina Marie Birk Andreas Rieckmann Thomas Hoffmann Christine Stabell Benn Dorthe Lisbeth Jeppesen Ole Pryds Thomas Nørrelykke Nissen |
spellingShingle |
Trine Mølbæk Jensen Signe Kjeldgaard Jensen Nina Marie Birk Andreas Rieckmann Thomas Hoffmann Christine Stabell Benn Dorthe Lisbeth Jeppesen Ole Pryds Thomas Nørrelykke Nissen Determinants of Bacille Calmette-Guérin scarification in Danish children Heliyon BCG vaccine BCG scar Non-specific effects Heterologous immunity |
author_facet |
Trine Mølbæk Jensen Signe Kjeldgaard Jensen Nina Marie Birk Andreas Rieckmann Thomas Hoffmann Christine Stabell Benn Dorthe Lisbeth Jeppesen Ole Pryds Thomas Nørrelykke Nissen |
author_sort |
Trine Mølbæk Jensen |
title |
Determinants of Bacille Calmette-Guérin scarification in Danish children |
title_short |
Determinants of Bacille Calmette-Guérin scarification in Danish children |
title_full |
Determinants of Bacille Calmette-Guérin scarification in Danish children |
title_fullStr |
Determinants of Bacille Calmette-Guérin scarification in Danish children |
title_full_unstemmed |
Determinants of Bacille Calmette-Guérin scarification in Danish children |
title_sort |
determinants of bacille calmette-guérin scarification in danish children |
publisher |
Elsevier |
series |
Heliyon |
issn |
2405-8440 |
publishDate |
2021-01-01 |
description |
Background: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for developing a BCG-scar and for BCG scar size following neonatal BCG vaccination. Methods: At three Danish hospitals, newborns were randomized 1:1 to BCG vaccination or no BCG vaccination. The infants were invited for a clinical examination at the ages of 3 and 13 months. At 13 months, the scar site was inspected and scar size measured. We investigated three groups of determinants; external, parental, and individual-level determinants on relative scar prevalence and differences in median scar sizes. Results: Among 2118 BCG vaccinated infants, 2039 (96 %) were examined at 13 months; 1857 of these (91 %) had developed a BCG-scar. Compared with Copenhagen University Hospital, Hvidovre (85 %), Copenhagen University Hospital, Rigshospitalet had a scar prevalence of 95 % (adjusted Prevalence ratio (aPR) = 1.24 [CI 95 %: 1.18 to 1.30]); it was 93 % at Kolding Hospital (aPR 1.27 [CI 95 %: 1.19 to 1.35]). Increasing vaccine experience was positively associated with developing a scar and with scar size. Conclusion: Across multiple potential determinants of BCG scaring and size, logistical factors dominated. The results support that injection technique is an important determinant of developing a scar. Given the strong link between having a BCG scar and subsequent health, improved BCG vaccination technique could play a major role for child health. |
topic |
BCG vaccine BCG scar Non-specific effects Heterologous immunity |
url |
http://www.sciencedirect.com/science/article/pii/S2405844020326001 |
work_keys_str_mv |
AT trinemølbækjensen determinantsofbacillecalmetteguerinscarificationindanishchildren AT signekjeldgaardjensen determinantsofbacillecalmetteguerinscarificationindanishchildren AT ninamariebirk determinantsofbacillecalmetteguerinscarificationindanishchildren AT andreasrieckmann determinantsofbacillecalmetteguerinscarificationindanishchildren AT thomashoffmann determinantsofbacillecalmetteguerinscarificationindanishchildren AT christinestabellbenn determinantsofbacillecalmetteguerinscarificationindanishchildren AT dorthelisbethjeppesen determinantsofbacillecalmetteguerinscarificationindanishchildren AT olepryds determinantsofbacillecalmetteguerinscarificationindanishchildren AT thomasnørrelykkenissen determinantsofbacillecalmetteguerinscarificationindanishchildren |
_version_ |
1724283359382732800 |